SCHEMBL21624520

SCHEMBL21624520

O=C(c1c(F)ccc(NS(=O)(=O)Cc2ccccc2)c1F)c1c[nH]c2ncc(-c3ccc(F)cc3)cc12

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 4/20 0.68
MAP3K20 Q9NYL2 2/20 0.68
MAP4K5 Q9Y4K4 2/20 0.68
RIPK2 O43353 1/20 0.68
ABCB11 O95342 1/20 0.68
EGFR P00533 1/20 0.68
KRAS P01116 1/20 0.68
RAF1 P04049 1/20 0.68
PGR P06401 1/20 0.68
RET P07949 1/20 0.68
CHRM2 P08172 1/20 0.68
ADORA3 P0DMS8 1/20 0.68
ARAF P10398 1/20 0.68
CHRM1 P11229 1/20 0.68
CHRM3 P20309 1/20 0.68
FECH P22830 1/20 0.68
KDR P35968 1/20 0.68
MAP2K2 P36507 1/20 0.68
TGFBR2 P37173 1/20 0.68
NEK2 P51955 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30866615 1.00 BRAF (0.68) BRAFMAP3K20MAP4K5RIPK2ABCB11
SCHEMBL29725806 0.94 BRAF (0.77) BRAFMAP3K20MAP4K5RIPK2ABCB11
SCHEMBL20399240 0.94 BRAF (0.77) BRAFMAP3K20MAP4K5RIPK2ABCB11
SCHEMBL21624517 0.93 BRAF (0.77) BRAFMAP3K20MAP4K5RIPK2ABCB11
SCHEMBL30866641 0.93 BRAF (0.77) BRAFMAP3K20MAP4K5RIPK2ABCB11
SCHEMBL21624496 0.92 BRAF (0.72) BRAFMAP3K20MAP4K5RIPK2ABCB11
SCHEMBL21625624 0.91 BRAF (0.65) BRAFMAP3K20MAP4K5RIPK2ABCB11
SCHEMBL29898534 0.91 BRAF (0.65) BRAFMAP3K20MAP4K5RIPK2ABCB11
SCHEMBL30866645 0.90 BRAF (0.74) BRAFMAP3K20MAP4K5RIPK2ABCB11
SCHEMBL21624497 0.90 BRAF (0.74) BRAFMAP3K20MAP4K5RIPK2ABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220281864-A1 PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH HEPAREGENIX GMBH (DE) 2022-09-08 US claimed
EP-3823968-A1 PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH HepaRegeniX GmbH (DE) 2021-05-26 EP claimed
WO-2020016243-A1 PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH HEPAREGENIX GMBH (DE) 2020-01-23 WO claimed
CN-112424201-B Protein kinase inhibitors that promote liver regeneration or reduce or prevent hepatocyte death 海帕瑞吉尼克斯股份有限公司 2024-04-02 CN disclosed
US-11912701-B2 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death HEPAREGENIX GMBH (DE) 2024-02-27 US disclosed
US-11912701-B2 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death HEPAREGENIX GMBH (DE) 2024-02-27 US disclosed
US-11912701-B2 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death HEPAREGENIX GMBH (DE) 2024-02-27 US disclosed
US-20220281864-A1 PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH HEPAREGENIX GMBH (DE) 2022-09-08 US disclosed
EP-3823968-A1 PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH HepaRegeniX GmbH (DE) 2021-05-26 EP disclosed
CN-112424201-A Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death 海帕瑞吉尼克斯股份有限公司 2021-02-26 CN disclosed
WO-2020016243-A1 PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH HEPAREGENIX GMBH (DE) 2020-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912701-B2 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death MAPK4, MAPK7, MAPK14 BRAF 64/4885MAP3K20 49/4885MAP4K5 43/4885
US-20220281864-A1 PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH MAPK4, MAPK7, MAPK14 BRAF 65/4885MAP3K20 48/4885MAP4K5 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.